Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / EFEMP1



This biomarker is also known as:
  • FBLN3,
  • fibulin 3,
  • MTLV,
  • S1-5,
  • Fibrillin-like protein,
  • DHRD,
  • EGF containing fibulin-like extracellular matrix protein 1,
  • Fibulin-3,
  • FBNL,
  • Extracellular protein S1-5,

View in BioMuta


EFEMP1, also known as fibulin-3, binds EGFR, the EGF receptor, inducing EGFR autophosphorylation and the activation of downstream signaling pathways. It may play a role in cell adhesion and migration, and may function as a negative regulator of chondrocyte differentiation. In the olfactory epithelium, it may regulate glial cell migration, differentiation and the ability of glial cells to support neuronal neurite outgrowth. EFEMP1 is up-regulated in malignant gliomas and may play a role in the agressive nature of these tumors by increasing glioma cell adhesiveness and invasive properties.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: One
QA State: Under Review


Inactivation of EFEMP1 due to DNA hypermethylation has been seen in lung, prostate, colorectal, breast, nasopharyngeal, and hepatocellular cancers. EFEMP1 has been shown to be up-regulated in pancreatic adenocarcinoma metastases and possibly glioblastomas.

Performance Comment

EFEMP1 (fibulin-3) levels may be helpful in the diagnosis and prognosis of pleural mesothelioma. Plasma fibulin-3 levels have been shown to differentiate healthy persons with exposure to asbestos from patients with mesothelioma. In conjunction with effusion fibulin-3 levels, plasma fibulin-3 levels can further differentiate mesothelioma effusions from other malignant and benign effusions.



Phase: One
QA State: Under Review


A single study of differences in gene expression between ovarian or primary peritoneal serous carcinomas and diffuse malignant peritoneal mesothelioma showed that EFEMP1 was overexpressed in all the mesotheliomas but in none of the ovarian or serous carcinomas.

Performance Comment

No additional ovarian data available.



Phase: One
QA State: Under Review


Performance Comment


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2015 Steering Committee Meeting

The next EDRN Steering Committee Meeting will take place March 31st through April 2nd, 2015, in Atlanta, Georgia.

Announcement 12/02/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh ( no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.